| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $49.7M | +12.5% | +65.1% |
| SG&A Expense | $7.3M | -3.3% | -21.6% |
| Operating Income | -$57.0M | -10.2% | -44.6% |
| Net Income | -$54.9M | -11.7% | -57.7% |
| EPS (Basic) | -$0.37 | -8.8% | -48.0% |
| EPS (Diluted) | -$0.37 | -8.8% | -48.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $139.4M | +5.4% | +75.3% |
| Current Assets | $192.8M | -16.4% | -44.0% |
| Total Assets | $229.1M | -13.4% | -39.5% |
| Current Liabilities | $43.6M | +7.2% | +117.4% |
| Total Liabilities | $67.7M | +3.3% | +43.4% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$140.4M | — | — |
| Capital Expenditures | $137K | — | — |
| Investing Cash Flow | $216.6M | — | — |
| Financing Cash Flow | $13.8M | — | — |
| Free Cash Flow | -$140.6M | — | — |
| $161.4M |
| -18.9% |
| -51.3% |